Mikita, N
Simonoff, E
Pine, D S
Goodman, R
Artiges, E
Banaschewski, T
Bokde, A L
Bromberg, U
Büchel, C
Cattrell, A
Conrod, P J
Desrivières, S
Flor, H
Frouin, V
Gallinat, J
Garavan, H
Heinz, A
Ittermann, B
Jurk, S
Martinot, J L
Paillère Martinot, M L
Nees, F
Papadopoulos Orfanos, D
Paus, T
Poustka, L
Smolka, M N
Walter, H
Whelan, R
Schumann, G
Stringaris, A
Article History
Received: 29 January 2016
Revised: 1 April 2016
Accepted: 20 April 2016
First Online: 28 June 2016
Competing interests
: Dr Banaschewski has served as an advisor or consultant to Bristol-Myers Squibb, Desitin Arzneimittel, Eli Lilly, Medice, Novartis, Pfizer, Shire, UCB and Vifor Pharma; he has received conference attendance support, conference support or speaking fees from Eli Lilly, Janssen McNeil, Medice, Novartis, Shire and UCB; and he is involved in clinical trials conducted by Eli Lilly, Novartis and Shire; the present work is unrelated to these relationships. Dr Gallinat has received research funding from the German Federal Ministry of Education and Research, AstraZeneca, Eli Lilly, Janssen-Cilag and Bristol-Myers Squibb; he has received speaking fees from AstraZeneca, Janssen-Cilag and Bristol-Myers Squibb. Dr Goodman is the owner of Youthinmind, Ltd., which provides no-cost and low-cost software and websites related to the Development and Well-Being Assessment and the Strengths and Difficulties Questionnaire. Ms Mikita received a one-off honorarium from John Wiley & Sons. Dr Stringaris has received grant or research support from the Guy's & St Thomas' Charity, University College London for a joint project with Johnson & Johnson, the Wellcome Trust and the National Institute for Health Research; he also receives royalties from Cambridge University Press and Oxford University Press. The remaining authors declare no conflict of interest.